Zensar Technologies Limited has published the transcript of its earnings call regarding the financial results for the quarter ended June 30, 2026. The conference call took place on July 30, 2026, at 08:30 a.m. (IST), providing stakeholders with management's commentary on the company's performance for Q1FY27. This disclosure ensures transparency and allows investors to review the detailed discussion surrounding the quarterly outcomes.

The transcript is now hosted on the company's website at https://www.zensar.com/investors/investor-corner . Zensar Technologies submitted this update to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 5, 2026. The filing serves as a continuation of the company's earlier communication dated July 27, 2026, which likely announced the preliminary results or scheduled the call.

Filing Details

The document was signed by Anand Daga, the Company Secretary of Zensar Technologies Limited. It carries the digital signature timestamped on August 5, 2026, at 20:43:28 IST. The submission includes the standard corporate stamp and references the company's scrip code (504067) and trading symbol (ZENSARTECH) for identification purposes.

Investor Access

Investors and analysts can access the full text of the discussion by visiting the investor corner section of the Zensar Technologies website. The transcript provides insights into management's perspective on operational performance, market conditions, and future outlook for the fiscal year 2027. As an RPG Group company, Zensar continues to maintain regular communication with its shareholder base through such disclosures.

This release is for informational and dissemination purposes only. The company requests that exchanges take the document on record as part of its regulatory compliance obligations under securities market norms.

Zensar Technologies Limited has confirmed that the merger of its US subsidiary Bridgeview Life Sciences LLC into Zensar Technologies Inc. became effective on August 1, 2026. The company disclosed that all requisite filings with relevant local authorities and state agencies were completed on July 30, 2026. This development marks a significant step in the broader restructuring plan approved by the Board of Directors on July 29, 2026, which aims to consolidate two US-based step-down subsidiaries into the material wholly owned subsidiary, Zensar Technologies Inc.

The second part of the restructuring, involving the merger of M3BI LLC with Zensar Technologies Inc., is currently underway. Filings for this transaction are in progress, with no specific effective date disclosed yet. The entire consolidation process is governed by internal group approvals and local regulatory requirements in the United States, rather than Indian shareholder approval, as it involves wholly owned subsidiaries.

The strategic rationale for merging Bridgeview Life Sciences LLC and M3BI LLC into Zensar Technologies Inc. remains focused on driving business synergies and enhancing operational efficiencies. By unifying control over operations across its North American footprint, Zensar Technologies seeks to streamline management structures and reduce administrative overheads. All three entities operate in the digital solutions and technology services sector, serving global organizations.

Financial Overview of Entities Involved

Financial details of the entities involved, based on standalone figures for the year ended March 31, 2026, underscore the scale of the integration. The following table summarises the key financial metrics of the entities participating in the restructuring:

Regulatory Compliance and Shareholder Impact

The transaction does not constitute a related-party transaction under Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as it involves wholly owned subsidiaries within the group structure. Consequently, there will be no change in the shareholding pattern of Zensar Technologies Limited consequent to this merger. No cash consideration or share exchange ratio is applicable since the transaction is internal to the group's US operations.

The proposal was initially considered by the Boards of the respective merging entities and Zensar Technologies Inc., USA. The disclosure regarding the effective date of the Bridgeview merger was made pursuant to Regulation 30(1) of the SEBI Listing Regulations, read with the SEBI Master Circular dated January 30, 2026. The company received intimation of the completion of filings at 03:00 a.m. (IST) on July 31, 2026.